版本:
中国

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

Nov 22 Bristol-Myers Squibb Co :

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin

* Approval allows for expanded marketing of Opdivo in relapsed or refractory CHL in all 28 member states of EU Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐